Medical devices industry venture financing deals in Q4 2020 total $2.3bn in US

Total medical devices industry venture financing deals in Q4 2020 worth $2.3bn were announced in the US, according to GlobalData’s deals database.

The value marked a decrease of 15.9% over the previous quarter and a drop of 3.6% when compared with the last four-quarter average of $2.39bn.

The US held a 59.8% share of the global medical devices industry venture financing deal value that totalled $3.84bn in Q4 2020.

In terms of deal activity, the US recorded 123 deals during Q4 2020, marking a drop of 27.2% over the previous quarter and a drop of 30.9% over the last four-quarter average.

The US medical devices industry venture financing deals in Q4 2020: Top deals

The top five medical devices industry venture financing deals accounted for 29.2% of the overall value during Q4 2020.

The combined value of the top five medical devices venture financing deals stood at $670m, against the overall value of $2.3bn recorded for the quarter.

The top five medical devices industry deals of Q4 2020 tracked by GlobalData were:

1) Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates’ $200m venture financing of Tempus Labs

2) The $150m venture financing of Singlera Genomics by CICC Kai Tak Fund, DETONG Capital Partners, FutureX Skyline Capital, Huamei International, Linden Asset Management, Prosperico Ventures, Proxima Ventures, Shanghai Free Trade Zone Fund Tao Capital, Shanghai Furong Investment, Shenzhen Green Pine Capital Partners and Wuxi Financial Investment

3) Hillhouse Capital Group, LYFE Capital, Orbimed Advisors and RA Capital Management’s $120m venture financing of Cytek Biosciences

4) The $100m venture financing of Avail Medsystems by 8VC, Baidu Ventures, Coatue Management, D1 Capital Partners, Lux Capital, Playground Global, Refactor Capital and Sonder Capital

5) Brookfield Technology Partners II, Builders VC, DCVC Management Co and Dragoneer Investment Group’s venture financing of Carbon Health Medical Group for $100m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.